Precipio Achieves Record Revenue and Positive Adjusted EBITDA in Q2 2026, Signifying Strong Turnaround and Growth Trajectory
NEW HAVEN, CT – August 17th, 2026 – Precipio, Inc. (NASDAQ: PRPO), a leading specialty cancer diagnostics company, today announced exceptional financial results for the second quarter ended June 30, 2026, marking a significant milestone with record-breaking revenue and a return to positive Adjusted EBITDA. These impressive figures underscore the company’s robust operational recovery and strengthening financial position.
For the first time in its history, Precipio surpassed the $7 million mark in quarterly revenue, achieving a record total revenue of $7.0 million. This represents a healthy increase from $6.7 million in Q1 2026 and a substantial 22% year-over-year growth compared to $5.7 million in Q2 2025. The growth was primarily driven by strong performance in both pathology revenue, which rose to $6.1 million (from $6.0 million in Q1), and product revenue, which saw a significant jump to $0.9 million (from $0.66 million in Q1).
A key highlight of the quarter is Precipio’s return to positive Adjusted EBITDA, reaching $0.4 million, a notable turnaround from $(0.2) million in Q1 2026. This positive shift is attributed to increased revenues and a reduction in stock-based compensation expenses by $0.2 million.
Further solidifying its financial health, Precipio generated $0.7 million in cash flow from operations during Q2 2026, leading to a total cash increase of $0.5 million. The company concluded the quarter with a strong cash balance exceeding $3 million, a significant improvement from $1.1 million in Q2 2025.
Ilan Danieli, CEO of Precipio, expressed his enthusiasm for the company’s performance, stating, "As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history. Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M. We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum."
Precipio, a B2i Digital Featured Company, is committed to addressing the critical issue of cancer misdiagnoses through innovative diagnostic products and services. Their mission focuses on developing solutions that deliver higher accuracy, improve laboratory workflow, and ultimately lead to better patient outcomes while reducing healthcare expenses. The company designs, tests, validates, and clinically utilizes its technologies in its own laboratories before commercializing them as proprietary products for the global laboratory community.
Investors and interested parties are invited to join a shareholder call on August 17th, 2026, at 5 PM ET, where management will provide a more in-depth discussion on the Q2 2026 performance, followed by a moderated Q&A session.
About Precipio
Precipio is a healthcare biotechnology company dedicated to revolutionizing cancer diagnostics. By developing cutting-edge diagnostic products and services, Precipio aims to combat the pervasive problem of cancer misdiagnosis. Their innovative technologies enhance diagnostic accuracy, streamline laboratory processes, and ultimately contribute to improved patient prognoses and reduced healthcare costs. Precipio’s approach involves in-house development, testing, and validation of its technologies, which are then commercialized to serve the global diagnostic community.
Further Information:
For more details on Precipio’s financial results, please refer to the company’s Form 10-Q filed today. Additional information about Precipio can be found on their website at https://www.precipiodx.com/ and by following their social media channels on X (@PrecipioDx), LinkedIn (Precipio), and Facebook.
Forward-Looking Statements:
This press release contains forward-looking statements as defined by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. Precipio disclaims any obligation to update these statements, except as required by law.
